Genetic Predisposition to CancerRAMP-BCNCT07911592
Breast Cancer Risk Assessment and Management Program
A study testing Patient nudge via text message and Patient nudge via phone call in people with Genetic Predisposition to Cancer, run by Abramson Cancer Center at Penn Medicine at 1 site in United States.
Trial summary
The objective of this project is to assess the implementation of evidence-based, digital tools to improve breast cancer risk assessment and related primary cancer prevention services for those at high risk for developing breast cancer. Read more about this study
- Who is it for?
- Ages 18 to 39 years, women onlyHealthy volunteers can take part
- Conditions the study is for
- Genetic Predisposition to Cancer
- What is being tested?
- Patient nudge via text message and Patient nudge via phone call
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 1,000 participants
- Where
- 1 siteUnited States
- Study dates
- 23 Sep 2026to Sep 2029
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 39 years
- Women only
- Healthy volunteers accepted
- Adult
Who may be able to join
- are between 18-39 years
- have Sex Assigned at Birth of female in EHR. If Sex Assigned at Birth is not available, Legal Sex of female.
- received care from Penn Primary care of OB/GYN (Past appointment within 1 year and future appointment within 3 months)
Who cannot join
- are younger than 18 or older than 39 because breast cancer risk assessment guidelines do not pertain to these groups. Furthermore, women 40 and older also qualify for standard of care breast cancer screening.
- have Sex Assigned at Birth of male in EHR because breast cancer risk assessment guidelines do not currently pertain to males. If Sex Assigned at Birth is not available, Legal Sex of male.
- Have been diagnosed with breast cancer via ICD-9 code C50.xx in problem list or medical history
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site
University of Pennsylvania
Philadelphia, Pennsylvania, 19104
About this study
Official title: Breast Cancer Risk Assessment and Management Program (RAMP-BC)
The objective of this project is to assess the implementation of evidence-based, digital tools to improve breast cancer risk assessment and related primary cancer prevention services for those at high risk for developing breast cancer.
Read the detailed description
The scientific aims of the study are:
Aim 1: To evaluate the impact of the addition of patient nudge strategies (SMS reminders v. patient phone support) to improve uptake of breast cancer risk assessment. (adoption). Clinical, social, and demographic factors associated with uptake will be a secondary outcome.
Aim 2: To estimate service delivery costs from the health system perspective by collecting data on team-member time (Implementation) Aim 3: To describe critical patient, provider, and systems facilitators and barriers for the implementation process using a multi-stakeholder, mixed-methods approach supported by the PRISM and RE-AIM conceptual frameworks (Adoption, Implementation, Maintenance).
Exploratory aim: To quantify the following clinical outcomes - incidence of high-risk of breast cancer determination, incidence of pathogenic variants identified, proportion of patients at high-risk of developing breast cancer with breast cancer screening imaging ordered within 3 months of high-risk determination, proportion of high-risk patients who complete initial breast cancer screening imaging within 6 months of order.
- Conditions
- Genetic Predisposition to Cancer
- Being tested
- Patient nudge via text message, Patient nudge via phone call
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Patient nudge via text messageOther
The intervention involves patient nudge via text message
Patient nudge via phone callOther
The intervention involves patient nudge via phone call from a study team member. The patient phone call nudge will consist of a study team member calling to inquire about receipt of EVA chatbot and barriers to completion.
| Study group | Role | What they receive |
|---|---|---|
| EVA Message only | Active comparator | EVA SMS reminders only Receives: Other: Patient nudge via text message |
| EVA Message + phone call | Experimental | EVA + patient phone support Receives: Other: Patient nudge via phone call |
What is being measured
The primary outcome is the main question the study is designed to answer.
Uptake of EVA with initial SMS contact
Uptake is the proportion of subjects who engage the EVA within the first month after contact
Measured: 1 month
Uptake of EVA after patient nudge
Uptake will be summarized as a proportion of individuals who adopt EVA after patient nudge compared to those with no additional nudge. The effect of additional patient support is a comparison of proportions and will be summarized as an odds ratio
Measured: 3 months
Secondary outcomes (3)
Uptake of digital counseling intervention
Proportion of participants eligible for genetic testing who proceed with the digital counseling intervention
Measured: 4 months
Uptake of genetic testing
Proportion of participants eligible for genetic testing who complete genetic testing
Measured: 3 months
Uptake of breast imaging
Proportion of participants deemed at elevated risk for breast cancer who complete screening breast imaging
Measured: 12 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted3 Nov 2026
- Study start23 Sep 2026
- Primary completionSep 2028 (estimated)
- Study completionSep 2029 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Genetic Predisposition to CancerStudies of the same condition, open and under way.
- More trials run by Abramson Cancer Center at Penn MedicineThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Health services research
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 1,000 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Abramson Cancer Center at Penn Medicine
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07911592
- Sponsor's protocol ID
- 26-7107
- Acronym
- RAMP-BC
- Status last verified
- Oct 2026
- First submitted
- 28 Oct 2026
- Last updated
- 3 Nov 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 3 Nov 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Breast Cancer Risk Assessment and Management Program (RAMP-BC)
- ClinicalTrials.gov ID
- NCT07911592
- Acronym / sponsor ID
- RAMP-BC / 26-7107
- Conditions
- Genetic Predisposition to Cancer
- Study type
- Interventional
- Recruitment status
- Enrolling by invitation
- Enrolment
- 1,000 participants (estimated)
- Lead sponsor
- Abramson Cancer Center at Penn MedicineUniversity, hospital or other
- Study start
- 23 Sep 2026 (actual)
- Primary completion
- Sep 2028 (estimated)
- Study completion
- Sep 2029 (estimated)
- First posted
- 3 Nov 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The objective of this project is to assess the implementation of evidence-based, digital tools to improve breast cancer risk assessment and related primary cancer prevention services for those at high risk for developing breast cancer.
Detailed description
The scientific aims of the study are:
Aim 1: To evaluate the impact of the addition of patient nudge strategies (SMS reminders v. patient phone support) to improve uptake of breast cancer risk assessment. (adoption). Clinical, social, and demographic factors associated with uptake will be a secondary outcome.
Aim 2: To estimate service delivery costs from the health system perspective by collecting data on team-member time (Implementation) Aim 3: To describe critical patient, provider, and systems facilitators and barriers for the implementation process using a multi-stakeholder, mixed-methods approach supported by the PRISM and RE-AIM conceptual frameworks (Adoption, Implementation, Maintenance).
Exploratory aim: To quantify the following clinical outcomes - incidence of high-risk of breast cancer determination, incidence of pathogenic variants identified, proportion of patients at high-risk of developing breast cancer with breast cancer screening imaging ordered within 3 months of high-risk determination, proportion of high-risk patients who complete initial breast cancer screening imaging within 6 months of order.
Study design
- Primary purpose
- Health services research
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| EVA Message only | Active comparator | Other: Patient nudge via text messageEVA SMS reminders only |
| EVA Message + phone call | Experimental | Other: Patient nudge via phone callEVA + patient phone support |
Who may qualify
- Ages
- 18 to 39 years
- Sex
- Female only
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (3 listed)
- are between 18-39 years
- have Sex Assigned at Birth of female in EHR. If Sex Assigned at Birth is not available, Legal Sex of female.
- received care from Penn Primary care of OB/GYN (Past appointment within 1 year and future appointment within 3 months)
Key exclusion criteria (3 listed)
- are younger than 18 or older than 39 because breast cancer risk assessment guidelines do not pertain to these groups. Furthermore, women 40 and older also qualify for standard of care breast cancer screening.
- have Sex Assigned at Birth of male in EHR because breast cancer risk assessment guidelines do not currently pertain to males. If Sex Assigned at Birth is not available, Legal Sex of male.
- Have been diagnosed with breast cancer via ICD-9 code C50.xx in problem list or medical history
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Patient nudge via text messageThe intervention involves patient nudge via text message | Other | EVA Message only |
| Patient nudge via phone callThe intervention involves patient nudge via phone call from a study team member. The patient phone call nudge will consist of a study team member calling to inquire about receipt of EVA chatbot and barriers to completion. | Other | EVA Message + phone call |
Primary outcome
Uptake of EVA with initial SMS contact
Time frame: 1 month
Uptake is the proportion of subjects who engage the EVA within the first month after contact
Uptake of EVA after patient nudge
Time frame: 3 months
Uptake will be summarized as a proportion of individuals who adopt EVA after patient nudge compared to those with no additional nudge. The effect of additional patient support is a comparison of proportions and will be summarized as an odds ratio
3 secondary outcomes
Uptake of digital counseling intervention
Time frame: 4 months
Uptake of genetic testing
Time frame: 3 months
Uptake of breast imaging
Time frame: 12 months
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 3 Nov 2026.
- Individual participant dataSharing planned: No
Related trials for Genetic Predisposition to Cancer
RecruitingObservational study
Rare Tumors and Cancer Predisposition in Individuals and Families
Cancer, Hereditary Neoplasms
RecruitingObservational study
Hereditary Leiomyomatosis Renal Cell Cancer - Study of the Genetic Cause and the Predisposition to Renal Cancer
Renal Tumor Histology, Cutaneous Leiomyoma
Active, not recruitingObservational study
The IMPACT Study - Identification of Men With a Genetic Predisposition to ProstAte Cancer
Prostate Cancer, BRCA Mutation
RecruitingObservational study
Analysing Outcomes After Prostate Cancer Diagnosis and Treatment in Carriers of Rare Germline Mutations
Prostate Cancer
RecruitingObservational study
Pancreatic Cancer Early Detection Consortium
Pancreas Cancer, Pancreas Cyst
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Patient nudge via text message and Patient nudge via phone call in people with Genetic Predisposition to Cancer, run by Abramson Cancer Center at Penn Medicine at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: enrolling by invitation, as of the sponsor's last update on 3 Nov 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Uptake of EVA with initial SMS contact (time frame: 1 month). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Nov 2026.